Expert: Professor Andreas Hochhaus Director of the Department of Hematology and Medical Oncology Jena University Hospital (Germany)

Program:
Treatment of CML patients after failure of 2 TKIs

• Choice of an alternative TKI
• Intolerance after ≥ 2 lines of TKIs
• Allogeneic HCT in CML in Europe: EDMT Report
• What is the right dose?  Salvage / frontline
• Results from the BYOND study and the OPTIC trial
• Asciminib - an investigational first in class STAMP inhibitor
• Asciminib study results: phase 1 study / combination with IM, NIL, or DAS,
  ASCEMBL study, phase 3b treatment optimization study
• Other new drugs in development incl. ELVN-001, PF114, olverembatinib and vodobatinib
• Conclusion: expanding arsenal to fight failure of TKIs

If you have any questions or comments to the speaker, please email info@cml-foundation.org.